Objectif
Relieving serious health-related suffering for patients in palliative and end-of-life care, be it physical, psychological, social, or spiritual, is a global ethical responsibility. However, the profound psycho-emotional and existential distress entailed by such suffering, despite often being an enormous burden for both patients and their loved ones, remains a field largely overlooked by health care providers and the scientific community. Those people may develop mood or anxiety disorder for which neither non-pharmacological nor pharmacological interventions exist. In this context, we believe it is now time to target these unmet needs in the palliative care population. We want to initiate a paradigm shift at the boundaries between palliative care, psychiatry, psychology, neuroscience, and spiritual care. Our starting point is the preliminary results being reported for administration of psilocybin, the main psychoactive compound of so-called ‘psychedelic mushrooms’, in patients with depression. The objective of our project is thus to examine the clinical effect of a cutting-edge, individualised and patient-centred, open and standardised Psilocybin Therapy, addressing these unmet needs of patients in palliative care. We will show high quality evidence via a multi-centre Randomised Clinical Trial of the value of our therapeutic model in patients (and for the following four conditions: COPD, Atypical Parkinsonian Disorders, ALS, and Multiple Sclerosis), their loved ones and care providers, in a diverse sample of the European population, in addition to better understand the mechanisms of therapeutic change of our model. Finally, our project will establish a sustainable, multi-disciplinary, ecosystem of key European stakeholders jointly contributing to the medical use of psychedelic research and innovation, paving the way towards an ethical and cost-effective deployment of such a new line of care for patients in European palliative care service providers.
Champ scientifique
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
9713 GZ Groningen
Pays-Bas
Voir sur la carte
Participants (18)
75647 Uppsala
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
1165 Kobenhavn
Voir sur la carte
111 37 Stockholm
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
1107TN AMSTERDAM
Voir sur la carte
31080 Pamplona
Voir sur la carte
751 05 Uppsala
Voir sur la carte
1400-038 Lisboa
Voir sur la carte
10691 Stockholm
Voir sur la carte
9712CP Groningen
Voir sur la carte
250 67 Klecany
Voir sur la carte
1800 Vilvoorde
Voir sur la carte
10430 Rosiere Pres Troyes
Voir sur la carte
3400 Hillerod
Voir sur la carte
1000 BRUSSELS
Voir sur la carte
114 32 STOCKHOLM
Voir sur la carte
3818 LE AMERSFOORT
Voir sur la carte
67000 Strasbourg
Voir sur la carte
106 40 STOCKHOLM
Voir sur la carte